Akron Children's > For Families & Patients > Research > Pediatric Clinical Studies > Open Clinical Studies
Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP
Full IRB Study Title:
Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP
IRB Study ID: 23875646
See complete study information on clinicaltrials.gov.
Study Sponsor:
CSL Behring
We are currently recruiting
If you are interested in this study or have questions about your child's eligibility, please contact:
Hilary Tonni, Rebecca D. Considine Research Institute: 330-543-4734
Who May Qualify:
Male or female patients 2 to <17 years of age with confirmed or possible chronic inflammatory demyelinating polyneuropathy (CIDP)
Who Does NOT Qualify:
Patients with:
- History or family history of inherited neuropathy
- Diagnosed developmental delay or regression
- History of thrombotic episode
- Known or suspected hypersensitivity to Privigen
- Known allergic or other severe reactions to blood products
- Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study
- Pregnant or breastfeeding mother
Lead Investigator
Ian Rossman, MD, PhD
Pediatric Neurologist
NeuroDevelopmental Science CenterPediatric Neuromuscular ClinicPediatric NeurologyMitochondrial Center
